Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.

Croft CL, Cruz PE, Ryu DH, Ceballos-Diaz C, Strang KH, Woody BM, Lin WL, Deture M, Rodríguez-Lebrón E, Dickson DW, Chakrabarty P, Levites Y, Giasson BI, Golde TE.

J Exp Med. 2019 Feb 15. pii: jem.20182184. doi: 10.1084/jem.20182184. [Epub ahead of print]

PMID:
30770411
2.

Designing antibodies against LRRK2-targeted tau epitopes.

Hamm M, Ladd TB, Levites Y, Golde TE, Giasson BI, Lewis J.

PLoS One. 2018 Sep 27;13(9):e0204367. doi: 10.1371/journal.pone.0204367. eCollection 2018.

3.

Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.

Croft CL, Moore BD, Ran Y, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

PLoS One. 2018 Apr 2;13(4):e0195211. doi: 10.1371/journal.pone.0195211. eCollection 2018.

4.

Short Aβ peptides attenuate Aβ42 toxicity in vivo.

Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, Ladd TB, Ran Y, Levites Y, Kukar TL, Kurian JJ, McKenna R, Koo EH, Borchelt DR, Janus C, Rincon-Limas D, Fernandez-Funez P, Golde TE.

J Exp Med. 2018 Jan 2;215(1):283-301. doi: 10.1084/jem.20170600. Epub 2017 Dec 5.

5.

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.

Strang KH, Goodwin MS, Riffe C, Moore BD, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

Acta Neuropathol Commun. 2017 Jul 31;5(1):58. doi: 10.1186/s40478-017-0458-0.

6.

Strain-specific Fibril Propagation by an Aβ Dodecamer.

Dean DN, Das PK, Rana P, Burg F, Levites Y, Morgan SE, Ghosh P, Rangachari V.

Sci Rep. 2017 Jan 18;7:40787. doi: 10.1038/srep40787.

7.

Holdase activity of secreted Hsp70 masks amyloid-β42 neurotoxicity in Drosophila.

Fernandez-Funez P, Sanchez-Garcia J, de Mena L, Zhang Y, Levites Y, Khare S, Golde TE, Rincon-Limas DE.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5212-21. doi: 10.1073/pnas.1608045113. Epub 2016 Aug 16.

8.

Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.

Montgomery KS, Edwards G 3rd, Levites Y, Kumar A, Myers CE, Gluck MA, Setlow B, Bizon JL.

Hippocampus. 2016 Apr;26(4):455-71. doi: 10.1002/hipo.22535. Epub 2015 Oct 19.

9.

Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease.

Fernandez-Funez P, Zhang Y, Sanchez-Garcia J, de Mena L, Khare S, Golde TE, Levites Y, Rincon-Limas DE.

Hum Mol Genet. 2015 Nov 1;24(21):6093-105. doi: 10.1093/hmg/ddv321. Epub 2015 Aug 7.

10.

IFN-γ promotes τ phosphorylation without affecting mature tangles.

Li A, Ceballos-Diaz C, DiNunno N, Levites Y, Cruz PE, Lewis J, Golde TE, Chakrabarty P.

FASEB J. 2015 Oct;29(10):4384-98. doi: 10.1096/fj.15-275834. Epub 2015 Jul 8.

11.

A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Levites Y, O'Nuallain B, Puligedda RD, Ondrejcak T, Adekar SP, Chen C, Cruz PE, Rosario AM, Macy S, Mably AJ, Walsh DM, Vidal R, Solomon A, Brown D, Rowan MJ, Golde TE, Dessain SK.

J Neurosci. 2015 Apr 22;35(16):6265-76. doi: 10.1523/JNEUROSCI.5109-14.2015.

12.

Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction.

Kim JY, Grunke SD, Levites Y, Golde TE, Jankowsky JL.

J Vis Exp. 2014 Sep 15;(91):51863. doi: 10.3791/51863.

13.

Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.

Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A, Crosby KW, Cruz PE, DiNunno NM, Janus C, Ceballos-Diaz C, Borchelt DR, Golde TE, Chakrabarty P, Levites Y.

Mol Ther. 2015 Jan;23(1):53-62. doi: 10.1038/mt.2014.180. Epub 2014 Sep 17.

14.

Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein.

Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, Ran Y, Golde TE, Giasson BI.

Acta Neuropathol Commun. 2013 Jul 17;1:38. doi: 10.1186/2051-5960-1-38.

15.

Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.

Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y.

PLoS One. 2013 Jun 25;8(6):e67680. doi: 10.1371/journal.pone.0067680. Print 2013.

16.

Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.

Clippinger AK, D'Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A, Carlomagno Y, Chakrabarty P, Cook C, Golde TE, Levites Y, Ranum L, Schultheis PJ, Xu G, Petrucelli L, Sahara N, Dickson DW, Giasson B, Lewis J.

Acta Neuropathol. 2013 Jul;126(1):39-50. doi: 10.1007/s00401-013-1123-8. Epub 2013 May 11.

17.

Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo.

Kim JY, Ash RT, Ceballos-Diaz C, Levites Y, Golde TE, Smirnakis SM, Jankowsky JL.

Eur J Neurosci. 2013 Apr;37(8):1203-20. doi: 10.1111/ejn.12126. Epub 2013 Jan 24.

18.

Aβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo.

Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW.

Nat Commun. 2012;3:1009. doi: 10.1038/ncomms2013.

19.

Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains.

Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE.

Alzheimers Res Ther. 2012 May 23;4(3):18. doi: 10.1186/alzrt121.

20.

Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP.

Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR.

J Alzheimers Dis. 2012;28(4):961-9. doi: 10.3233/JAD-2011-111196.

PMID:
22156046
21.

Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.

Boddapati S, Levites Y, Sierks MR.

J Mol Biol. 2011 Jan 14;405(2):436-47. doi: 10.1016/j.jmb.2010.10.054. Epub 2010 Nov 10.

PMID:
21073877
22.

Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.

Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P.

FASEB J. 2010 Feb;24(2):548-59. doi: 10.1096/fj.09-141754. Epub 2009 Oct 13.

23.

Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.

Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ.

Mol Ther. 2009 Dec;17(12):2031-40. doi: 10.1038/mt.2009.174. Epub 2009 Jul 28.

24.

Quantitative and mechanistic studies of Abeta immunotherapy.

Golde TE, Das P, Levites Y.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):31-49. Review.

PMID:
19275635
25.

BRI2 (ITM2b) inhibits Abeta deposition in vivo.

Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin SG, Graff-Radford N, Dickson D, Rosenberry T, Golde TE.

J Neurosci. 2008 Jun 4;28(23):6030-6. doi: 10.1523/JNEUROSCI.0891-08.2008.

26.

Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis.

Laifenfeld D, Patzek LJ, McPhie DL, Chen Y, Levites Y, Cataldo AM, Neve RL.

J Neurosci. 2007 Jul 4;27(27):7141-53.

27.

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE.

J Neurosci. 2006 Nov 15;26(46):11923-8. Erratum in: J Neurosci. 2006 Dec 6;26(49):preceding 12847.

28.

Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.

Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE.

FASEB J. 2006 Dec;20(14):2576-8. Epub 2006 Oct 26.

PMID:
17068112
29.

Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.

Das P, Smithson LA, Price RW, Holloway VM, Levites Y, Chakrabarty P, Golde TE.

J Neuroinflammation. 2006 Jul 26;3:17.

30.

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.

Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE.

J Clin Invest. 2006 Jan;116(1):193-201. Epub 2005 Dec 8.

31.

Neuroprotective strategies in Parkinson's disease : an update on progress.

Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB.

CNS Drugs. 2003;17(10):729-62. Review.

PMID:
12873156
32.
34.
35.
36.

Supplemental Content

Loading ...
Support Center